Clinical Trials Browser

Withdrawn × decitabine and cedazuridine drug combination × Clear all

NCT06297629 2026-02-24

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Withdrawn

Classical hematologyMyeloid

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

NCT06351306 2025-03-24

DEC-C and Thioguanine for R/R AML

Phase 2 Withdrawn

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT06113289 2025-03-12

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05456269 2023-10-03

BISECT

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04013880 2020-07-07

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute